Atrial fibrillation, stroke, and acute antithrombotic therapy.
Bath
Philip M
PM
D001241:Aspirin / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D055502:Secondary Prevention; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology*; D000078222:Tinzaparin; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000517:prevention & control
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin; D001241:Aspirin